BioPharma Resources

Company · BAYRY

Bayer

Includes drugs filed under related and acquired sponsor names. Trials are searched under: Bayer.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

99

51 still marketed

Novel approvals

32

Approvals since 2021

22

Originals and new uses

Phase 3 trials

319

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Sunharbo approved NovelPriority reviewNov 9, 2026
  • Kerendia new use Priority reviewSep 16, 2026
  • Hyrnuo new use Priority reviewOrphanSep 9, 2026
  • Ambelvist approved NovelOrphanJun 12, 2026
  • Hyrnuo approved NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanNov 19, 2025
  • Lynkuet approved NovelOct 24, 2025
  • Kerendia new use Priority reviewJul 11, 2025
  • Nubeqa new use Jun 3, 2025
  • Vitrakvi new use OrphanApr 9, 2025
  • Vitrakvi new use OrphanApr 9, 2025

Drugs in development (7)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

Recruiting Phase 3 trials

Largest first.

Marketed drugs (51)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.